This post was contributed by Barry A. Siegel, MD, professor of radiology at Washington University School of Medicine, IDEAS Study co-investigator, and previously co-chair of the National Oncologic PET Registry (NOPR).
IDEAS Study results published this week in JAMA confirm that amyloid PET imaging serves a vital role in the management and diagnosis of the 5.5 million Americans suffering with Alzheimer’s – the nation’s sixth leading cause of death.
PET imaging used to detect Alzheimer’s-related plaques in the brain changed management of nearly two-thirds of patients with mild cognitive impairment and dementia – and diagnosis of the cause of these effects in nearly a third of such patients.
What’s more, the study results are generalizable across much of the US population as participating sites included community clinics, freestanding imaging centers and other non-academic settings – in addition to large teaching hospitals.
At present, there is no cure for Alzheimer’s disease – but research is actively ongoing on many fronts.
I am proud that the American College of Radiology managed this landmark trial and that radiologists are such a large part of this great effort.
Please share your thoughts in the comments section below and join the discussion on Engage (login required).